Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Aservo® EquiHaler® now available in the UK and Ireland
The inhaler marks more than a decade of collaboration between human pharma and animal health businesses.

Product allows medication to be inhaled deep into horses’ lungs.
 
The first inhaled treatment for severe equine asthma is now available in the UK and Ireland.

Manufactured by Boehringer Ingelheim, the Aservo® EquiHaler® marks more than a decade of collaboration between human pharma and Boehringer’s animal health business.

The inhaler incorporates Soft Mist Technology®, which is found in the Respimat® inhaler used in human respiratory disease. This allows the active ingredient to be inhaled deep into the horses’ lungs.

"It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation,” commented Dr Marc Laemmer, head of equine in UK & Ireland.

“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Our team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.”

He continues: “The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."

The active ingredient in the Aservo® EquiHaler® is ciclesonide - a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.

It does not use a propellant, meaning that using the device does not contribute to harmful greenhouse gas emissions. It has also been manufactured from 50 per cent recycled materials.

Featuring an ergonomic handle, dosing lever, and nostril adapter, the Aservo® EquiHaler®  has been awarded the prestigious Red Dot Award for Product Design.



Become a member or log in to add this story to your CPD history

Kennel Club appoints new chief executive

News Story 1
 The Kennel Club has announced the appointment of Mark Beazley, who was previously Cats Protection's director of operations, as chief executive. Mark replaces Rosemary Smart, who stepped down from the role in April after 18 years.

Mark has held several senior strategic and executive roles, including executive director at Dogs Trust Ireland and chair of the Companion Animal Working Group at Eurogroup for Animals. He was also heavily involved in the establishment of the Eu Cat and Dog Alliance.

Mark will take up his new role in October. 

Click here for more...
News Shorts
International Cat Care appoints new head of veterinary division

International Cat Care (ICC) has announced the appointment of Nathalie Dowgray as head of the charity's veterinary division.

Nathalie, who is an RCVS advanced practitioner in feline medicine, will lead the International Society of Feline Medicine (ISFM) and a play key role in advancing knowledge and research in feline medicine.

Claire Bessant, iCatCare's chief executive said: "We're absolutely delighted to be welcoming Nathalie to the charity. She brings a depth and breadth of feline expertise and understanding which fits perfectly with the charity's work and development, and her enthusiasm for cats is infectious."